Arcus Biosciences Q4 2023 Earnings Report

Arcus Biosciences EPS Results

• Actual EPS: -$1.08
• Consensus EPS: -$1.09
• Beat/Miss: Beat by +$0.01
• One Year Ago EPS: -$0.93

Arcus Biosciences Revenue Results

• Actual Revenue: $31.00 million
• Expected Revenue: $28.30 million
• Beat/Miss: Beat by +$2.70 million
• YoY Revenue Growth: -8.80%

Arcus Biosciences Announcement Details

• Quarter: Q4 2023
• Date: 2/21/2024
• Time: After Market Closes

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.